Brise Pharma

Executive Summary

Brise Pharma is a China-based biopharmaceutical company developing novel small molecule drugs for oncology and autoimmune diseases. Founded in 2018, the company focuses on modulating immune checkpoints and inflammatory pathways to address significant unmet medical needs. With a pipeline of compounds advancing from discovery into early clinical stages, Brise Pharma is currently in Phase 1 development. The company operates in the rapidly growing Chinese biotech sector, leveraging local expertise in drug discovery and clinical development. While still in early stages, its focus on immunomodulation positions it within a high-value therapeutic area. The company is privately held and has not disclosed its total funding or valuation. Given its early-stage profile and competitive landscape, Brise Pharma's success hinges on demonstrating clinical proof-of-concept and advancing candidates through regulatory milestones. The company represents a speculative investment opportunity with potential upside from pipeline progression, though significant risks remain typical for early-stage biotech.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 Data Readout for Lead Oncology Candidate30% success
• Q1 2027IND Filing for Autoimmune Disease Candidate40% success
• H2 2026Strategic Partnership or Licensing Deal25% success